Oxcarbazepine, a metabolite of carbamazepine, is used as an antiepileptic, 
analgesic for neuropathic pain and in the treatment of affective disorders. It 
has been approved by the Food and Drug Administration for partial seizures in 
adults as both adjunctive and monotherapy, and as adjunctive therapy in children 
aged from 2 to 16 years 
(http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_07_05_KP%20OxcarbazepineFDAlabel102005.pdf). 
We present a case of serotonin syndrome, which was precipitated by this medicine 
in a patient who had been predisposed by long-term treatment with sertraline, a 
selective serotonin reuptake inhibitor. This is the first reported fatality due 
to this drug interaction and only the second case of serotonin syndrome reported 
with oxcarbazepine. Physicians should consider this risk when prescribing the 
above combination.